Actuate Therapeutics Announces Poster Presentations at the 2022 AACR Annual Meeting

CHICAGO and FORT WORTH, Texas, March 28, 2022 (GLOBE NEWSWIRE) -- Actuate Therapeutics (Actuate), a clinical stage biopharmaceutical company, announced today two poster presentations from scientific collaborators at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place April 8-13, 2022, in New Orleans, Louisiana.

The abstracts are currently available on the AACR meeting website. The posters will be available online at following the presentations.

Poster Presentation Details:

  • Abstract 1831: 9-ING-41, a glycogen synthase kinase 3B inhibitor targets TP53 in pediatric brain tumors ATRT and ETMR
    Date/Time: Monday April 11, 2022, 1:30 PM - 5:00 PM
    Session: Mechanisms of Drug Action 1
    Presenter: Jason L. Haw, Levine Children's Hospital, Charlotte, NC
    Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 24
  • Abstract 4167: Small-molecule inhibition of glycogen synthase kinase-3 (GSK-3) increases the efficacy of anti-PD-L1 therapy in a murine model of microsatellite stable colorectal cancer (CRC); Therapeutic response correlates with T cell ratios and serum cytokine profiles in mice
    Date/Time: Wednesday, April 13, 2022, 9:00 AM - 12:30 PM ET
    Session: Combination Immunotherapies 1
    Presenter: Kelsey E. Huntington, Brown University, Providence, Rhode Island
    Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 36

About Actuate Therapeutics, Inc.
Actuate is a clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics for cancers and fibrotic diseases. For additional information, please visit the Company‚Äôs website at

Public Relations Dept.,
Actuate Therapeutics, Inc.
+1 (847) 986-4190

Primary Logo

Back to news